Review



recombinant human muc16  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    R&D Systems recombinant human muc16
    Recombinant Human Muc16, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 16 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+ca125+muc16+protein/Recombinant+Human+CA125%2FMUC16+Protein%2C+CF/us12325742-638-1-4
    Average 93 stars, based on 16 article reviews
    recombinant human muc16 - by Bioz Stars, 2026-10
    93/100 stars

    Images

    Related Articles

    Recombinant:

    Article Title: Sensitive on-chip detection of cancer antigen 125 using a DNA aptamer/carbon nanotube network platform
    Article Snippet: Accepted Manuscript Title: Sensitive On-Chip Detection of Cancer Antigen 125 Using a DNA Aptamer/Carbon Nanotube Network Platform Authors: Vinayakumar Gedi, Chung Kil Song, Gae Baik Kim, Jin Oh Lee, Eunkyul Oh, Bum Seok Shin, Mingi Jung, Jinhee Shim, Haiwon Lee, Young-Pil Kim PII: S0925-4005(17)31947-0 DOI: https://doi.org/10.1016/j.snb.2017.10.049 Reference: SNB 23353 To appear in: Sensors and Actuators B Received date: 11-7-2017 Revised date: 6-10-2017 Accepted date: 9-10-2017 Please cite this article as: Vinayakumar Gedi, Chung Kil Song, Gae Baik Kim, Jin Oh Lee, Eunkyul Oh, Bum Seok Shin, Mingi Jung, Jinhee Shim, Haiwon Lee, Young-Pil Kim, Sensitive On-Chip Detection of Cancer Antigen 125 Using a DNA Aptamer/Carbon Nanotube Network Platform, Sensors and Actuators B: Chemical https://doi.org/10.1016/j.snb.2017.10.049 This is a PDF file of an unedited manuscript that has been accepted for publication.. As a service to our customers we are providing this early version of the manuscript.. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form.

    Article Title: Label-Free Detection and Spectrometrically Quantitative Analysis of the Cancer Biomarker CA125 Based on Lyotropic Chromonic Liquid Crystal
    Article Snippet: .. Recombinant human CA125/MUC16 protein and anti-CA125 antibody employed in the LCLC-based immunoassay were manufactured by R&D Systems and Santa Cruz Biotechnology, respectively. ..

    Article Title: Protein assay and immunoassay based on nematic thermotropic and lyotropic liquid crystals quantitated by haze measurement
    Article Snippet: Haze measurement is the cornerstone for assessing the transparency or opaqueness of liquid crystals (LCs) in applications such as smart windows and display technologies.. In this study, we present a novel application of haze measurement as the quantitative approach for LC-based biosensing.. Protein assay with bovine serum albumin (BSA) as the protein standard and immunoassay of the cancer biomarker CA125 were performed with the thermotropic LC 5CB and the nematic phase of the lyotropic chromonic LC sunset yellow.



    Similar Products

    93
    R&D Systems recombinant human muc16
    Recombinant Human Muc16, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+ca125+muc16+protein/Recombinant+Human+CA125%2FMUC16+Protein%2C+CF/us12325742-638-1-4
    Average 93 stars, based on 1 article reviews
    recombinant human muc16 - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    93
    R&D Systems mucin 16 ca125
    FIGURE 2 | IPF stables showed decrease in <t>CA125</t> and POSTN levels 3 months post-antifibrotic treatment. Serum CA125 and POSTN levels in progressive (red) and stable (blue) at 0, 3, 6 and 12 months post-antifibrotic treatment in the (a and d) Cohort 1, (b and e) Cohort 2 and (c and f) Combined cohort. Box represents interquartile range with median and whiskers represent range. *p < 0.05, **p < 0.01, ***p < 0.001.
    Mucin 16 Ca125, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+ca125+muc16+protein/Recombinant+Human+CA125%2FMUC16+Protein%2C+CF/pm39919729-44-42-53
    Average 93 stars, based on 1 article reviews
    mucin 16 ca125 - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    93
    R&D Systems muc16 his
    FIGURE 2 | IPF stables showed decrease in <t>CA125</t> and POSTN levels 3 months post-antifibrotic treatment. Serum CA125 and POSTN levels in progressive (red) and stable (blue) at 0, 3, 6 and 12 months post-antifibrotic treatment in the (a and d) Cohort 1, (b and e) Cohort 2 and (c and f) Combined cohort. Box represents interquartile range with median and whiskers represent range. *p < 0.05, **p < 0.01, ***p < 0.001.
    Muc16 His, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+ca125+muc16+protein/Recombinant+Human+CA125%2FMUC16+Protein%2C+CF/pmc11737099-59-20-21
    Average 93 stars, based on 1 article reviews
    muc16 his - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    93
    R&D Systems recombinant human ca125 muc16 protein
    FIGURE 2 | IPF stables showed decrease in <t>CA125</t> and POSTN levels 3 months post-antifibrotic treatment. Serum CA125 and POSTN levels in progressive (red) and stable (blue) at 0, 3, 6 and 12 months post-antifibrotic treatment in the (a and d) Cohort 1, (b and e) Cohort 2 and (c and f) Combined cohort. Box represents interquartile range with median and whiskers represent range. *p < 0.05, **p < 0.01, ***p < 0.001.
    Recombinant Human Ca125 Muc16 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+ca125+muc16+protein/Recombinant+Human+CA125%2FMUC16+Protein%2C+CF/10__1016_slash_j__surfin__2024__105143-43-0-10
    Average 93 stars, based on 1 article reviews
    recombinant human ca125 muc16 protein - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    93
    R&D Systems 5609 mu 050
    FIGURE 2 | IPF stables showed decrease in <t>CA125</t> and POSTN levels 3 months post-antifibrotic treatment. Serum CA125 and POSTN levels in progressive (red) and stable (blue) at 0, 3, 6 and 12 months post-antifibrotic treatment in the (a and d) Cohort 1, (b and e) Cohort 2 and (c and f) Combined cohort. Box represents interquartile range with median and whiskers represent range. *p < 0.05, **p < 0.01, ***p < 0.001.
    5609 Mu 050, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+ca125+muc16+protein/Recombinant+Human+CA125%2FMUC16+Protein%2C+CF/10__1002_slash_pgr2__70004-80-31-29
    Average 93 stars, based on 1 article reviews
    5609 mu 050 - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    93
    R&D Systems muc16
    FIGURE 2 | IPF stables showed decrease in <t>CA125</t> and POSTN levels 3 months post-antifibrotic treatment. Serum CA125 and POSTN levels in progressive (red) and stable (blue) at 0, 3, 6 and 12 months post-antifibrotic treatment in the (a and d) Cohort 1, (b and e) Cohort 2 and (c and f) Combined cohort. Box represents interquartile range with median and whiskers represent range. *p < 0.05, **p < 0.01, ***p < 0.001.
    Muc16, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+ca125+muc16+protein/Recombinant+Human+CA125%2FMUC16+Protein%2C+CF/10__1002_slash_pgr2__70004-80-28-29
    Average 93 stars, based on 1 article reviews
    muc16 - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    93
    R&D Systems recombinant muc16
    a, Digestion of recombinant human <t>MUC16</t> (rhMUC16) with eStcE alone or nanobody-eStcE conjugates. b, rhMUC16 in-gel digest depicting degradation of eStcE-αHER2 conjugate after long-term storage at 4 °C. c, Representative flow plots showing cell surface binding of nanobody alone and eStcE-αHER2 on MCF10AHER2 cells measured by anti-His staining. d, Cell surface binding curves derived from mean fluorescence intensity from (c) (n = 3 biologically independent replicates). e, Kd values derived from (d). f, Representative flow plots showing cell surface binding of αHER2-eStcE on MCF10A±MUC1, ±HER2 cells measured by anti-His staining. Flow plot of αHER2-eStcE on MCF10AHER2 is shown in (c). g, Kd values derived from mean fluorescence intensity from (f) and Fig. 3c (n = 3 biologically independent replicates). The MCF10AHER2 bar depicts the same data as the αHER2-eStcE bar in (e). Data are mean ± s.d. P-values were determined using Tukey-corrected one-way ANOVA. *p < 0.05, **p < 0.005, ***p < 0.0005.
    Recombinant Muc16, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/recombinant+human+ca125+muc16+protein/Recombinant+Human+CA125%2FMUC16+Protein%2C+CF/pmc11018308-509-6-8
    Average 93 stars, based on 1 article reviews
    recombinant muc16 - by Bioz Stars, 2026-10
    93/100 stars
      Buy from Supplier

    Image Search Results


    FIGURE 2 | IPF stables showed decrease in CA125 and POSTN levels 3 months post-antifibrotic treatment. Serum CA125 and POSTN levels in progressive (red) and stable (blue) at 0, 3, 6 and 12 months post-antifibrotic treatment in the (a and d) Cohort 1, (b and e) Cohort 2 and (c and f) Combined cohort. Box represents interquartile range with median and whiskers represent range. *p < 0.05, **p < 0.01, ***p < 0.001.

    Journal: Respirology (Carlton, Vic.)

    Article Title: Pre-Treatment MMP7 Predicts Progressive Idiopathic Pulmonary Fibrosis in Antifibrotic Treated Patients.

    doi: 10.1111/resp.14894

    Figure Lengend Snippet: FIGURE 2 | IPF stables showed decrease in CA125 and POSTN levels 3 months post-antifibrotic treatment. Serum CA125 and POSTN levels in progressive (red) and stable (blue) at 0, 3, 6 and 12 months post-antifibrotic treatment in the (a and d) Cohort 1, (b and e) Cohort 2 and (c and f) Combined cohort. Box represents interquartile range with median and whiskers represent range. *p < 0.05, **p < 0.01, ***p < 0.001.

    Article Snippet: Serum levels of matrix metalloproteinase- 7 (MMP7), periostin (POSTN), C- X- C motif ligand 13 (CXCL13), intercellular adhesion molecule- 1 (ICAM- 1), osteopontin (OPN), C- C motif ligand 18 (CCL18), surfactant protein- D (SP- D), chitinase- 3- like protein- 1 (CHI3L1) and mucin 16 (CA125) were measured by ELISA using DuoSet ELISA Kits (R&D Systems, MN, USA) according to manufacturer's instruction.

    Techniques:

    a, Digestion of recombinant human MUC16 (rhMUC16) with eStcE alone or nanobody-eStcE conjugates. b, rhMUC16 in-gel digest depicting degradation of eStcE-αHER2 conjugate after long-term storage at 4 °C. c, Representative flow plots showing cell surface binding of nanobody alone and eStcE-αHER2 on MCF10AHER2 cells measured by anti-His staining. d, Cell surface binding curves derived from mean fluorescence intensity from (c) (n = 3 biologically independent replicates). e, Kd values derived from (d). f, Representative flow plots showing cell surface binding of αHER2-eStcE on MCF10A±MUC1, ±HER2 cells measured by anti-His staining. Flow plot of αHER2-eStcE on MCF10AHER2 is shown in (c). g, Kd values derived from mean fluorescence intensity from (f) and Fig. 3c (n = 3 biologically independent replicates). The MCF10AHER2 bar depicts the same data as the αHER2-eStcE bar in (e). Data are mean ± s.d. P-values were determined using Tukey-corrected one-way ANOVA. *p < 0.05, **p < 0.005, ***p < 0.0005.

    Journal: Nature biotechnology

    Article Title: Design of a mucin-selective protease for targeted degradation of cancer-associated mucins

    doi: 10.1038/s41587-023-01840-6

    Figure Lengend Snippet: a, Digestion of recombinant human MUC16 (rhMUC16) with eStcE alone or nanobody-eStcE conjugates. b, rhMUC16 in-gel digest depicting degradation of eStcE-αHER2 conjugate after long-term storage at 4 °C. c, Representative flow plots showing cell surface binding of nanobody alone and eStcE-αHER2 on MCF10AHER2 cells measured by anti-His staining. d, Cell surface binding curves derived from mean fluorescence intensity from (c) (n = 3 biologically independent replicates). e, Kd values derived from (d). f, Representative flow plots showing cell surface binding of αHER2-eStcE on MCF10A±MUC1, ±HER2 cells measured by anti-His staining. Flow plot of αHER2-eStcE on MCF10AHER2 is shown in (c). g, Kd values derived from mean fluorescence intensity from (f) and Fig. 3c (n = 3 biologically independent replicates). The MCF10AHER2 bar depicts the same data as the αHER2-eStcE bar in (e). Data are mean ± s.d. P-values were determined using Tukey-corrected one-way ANOVA. *p < 0.05, **p < 0.005, ***p < 0.0005.

    Article Snippet: For recombinant human MUC16 digestion experiments, recombinant MUC16 (R&D Systems) was left unlabeled but was otherwise treated as described above.

    Techniques: Recombinant, Binding Assay, Staining, Derivative Assay, Fluorescence

    a-b, 4T07MUC1 cells (a) and OVCAR-3 cells (b) were treated with 50 nM StcE for 2 hours, washed 1x with 2 mM EDTA followed by 5x with DPBS, then cultured for the indicated times. Cells were then lysed and subjected to Western blotting for MUC1 (a) and MUC16 (b). Mucin bands are denoted by black arrows. c, Bioluminescent imaging of animals described in Fig. 4e. d, Total flux measurements quantified from (c). e, Plot depicting mouse masses of animals described in Fig. 4e. f-g, H&E staining of lungs from PBS-treated (f) or αHER2-eStcE treated (g) animals (n = 7 animals per group, 2 slides per animal). Percent area of lung metastases is quantified in Fig. 4g. h, Quantification of images from Supplementary Fig. 6 using the IHC profiler plugin in ImageJ. Percent positive corresponds to positive DAB staining in the cytosol. i, Quantification of images from Supplementary Fig. 7 using the IHC profiler plugin in ImageJ. Percent positive corresponds to positive DAB staining in the cytosol. j, Quantification of images from Supplementary Fig. 8 using the IHC profiler plugin in ImageJ. Percent positive corresponds to positive DAB staining in the nucleus. k, Treatment regimen for BALB/c mice injected intravenously (I.V.) via tail vein with 4T07MUC1, HER2 cells. Doxycycline was included in the chow for the duration of the experiment to maintain MUC1 ectodomain expression. αHER2-eStcE at 10 mg/kg or an equimolar quantity of αHER2-eStcEE447D or αGFP-eStcE were injected I.V. every other day starting on day 0 (n = 9 animals per group). l, Total flux of the indicated days normalized to the total flux on day 0 for each mouse quantified from Supplementary Fig. 10. Data are mean ± s.e.m. P-values were determined using two-tailed Mann-Whitney test (d-e), two-tailed unpaired t-test (h-j), or Tukey-corrected one-way ANOVA (l). *p < 0.05, **p < 0.005, ***p < 0.0005.

    Journal: Nature biotechnology

    Article Title: Design of a mucin-selective protease for targeted degradation of cancer-associated mucins

    doi: 10.1038/s41587-023-01840-6

    Figure Lengend Snippet: a-b, 4T07MUC1 cells (a) and OVCAR-3 cells (b) were treated with 50 nM StcE for 2 hours, washed 1x with 2 mM EDTA followed by 5x with DPBS, then cultured for the indicated times. Cells were then lysed and subjected to Western blotting for MUC1 (a) and MUC16 (b). Mucin bands are denoted by black arrows. c, Bioluminescent imaging of animals described in Fig. 4e. d, Total flux measurements quantified from (c). e, Plot depicting mouse masses of animals described in Fig. 4e. f-g, H&E staining of lungs from PBS-treated (f) or αHER2-eStcE treated (g) animals (n = 7 animals per group, 2 slides per animal). Percent area of lung metastases is quantified in Fig. 4g. h, Quantification of images from Supplementary Fig. 6 using the IHC profiler plugin in ImageJ. Percent positive corresponds to positive DAB staining in the cytosol. i, Quantification of images from Supplementary Fig. 7 using the IHC profiler plugin in ImageJ. Percent positive corresponds to positive DAB staining in the cytosol. j, Quantification of images from Supplementary Fig. 8 using the IHC profiler plugin in ImageJ. Percent positive corresponds to positive DAB staining in the nucleus. k, Treatment regimen for BALB/c mice injected intravenously (I.V.) via tail vein with 4T07MUC1, HER2 cells. Doxycycline was included in the chow for the duration of the experiment to maintain MUC1 ectodomain expression. αHER2-eStcE at 10 mg/kg or an equimolar quantity of αHER2-eStcEE447D or αGFP-eStcE were injected I.V. every other day starting on day 0 (n = 9 animals per group). l, Total flux of the indicated days normalized to the total flux on day 0 for each mouse quantified from Supplementary Fig. 10. Data are mean ± s.e.m. P-values were determined using two-tailed Mann-Whitney test (d-e), two-tailed unpaired t-test (h-j), or Tukey-corrected one-way ANOVA (l). *p < 0.05, **p < 0.005, ***p < 0.0005.

    Article Snippet: For recombinant human MUC16 digestion experiments, recombinant MUC16 (R&D Systems) was left unlabeled but was otherwise treated as described above.

    Techniques: Cell Culture, Western Blot, Imaging, Staining, Injection, Expressing, Two Tailed Test, MANN-WHITNEY